LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Agilent Technologies to Acquire Multiplicom

By LabMedica International staff writers
Posted on 03 Jan 2017
Agilent Technologies Inc. (Santa Clara, CA, USA) has entered into a definitive agreement to acquire European diagnostics company Multiplicom N.V. (Niel, Belgium), for approximately EUR 68 million in cash.

Agilent, which is present in life sciences, diagnostics and applied chemical markets, provides instruments, software, services and consumables for the entire laboratory workflow. Multiplicom develops, manufactures and commercializes molecular-diagnostic solutions, provided as kits. These solutions enable clinical laboratories to identify the DNA variants that are associated with a genetic disease or predisposition in patients, or that may steer cancer therapy or identify congenital defects early in pregnancy.

"The acquisition of Multiplicom significantly strengthens our presence in the genomics market," said Herman Verrelst, vice president and general manager of Agilent's Genomics Division. "Multiplicom's products and technology help expand our target-enrichment portfolio and enhance our next-generation sequencing workflow capabilities – providing immediate scale in adjacent markets.”

"Multiplicom is excited to be a part of Agilent and for the opportunity to offer our products and technology to a global customer base," said Dirk Pollet, Multiplicom's CEO.

Related Links:
Agilent Technologies
Multiplicom

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Platelet Function Analyzer
PL-12
Automated Urinalysis Solution
UN-9000
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10

Latest Industry News

New NHS Partnership Expands Access to Epigenetic CNS Tumor Classifiers
03 Jan 2017  |   Industry

Fujirebio Expands Access to Automated Blood-Based Neurology Testing in Canada
03 Jan 2017  |   Industry

Natera ctDNA Test to Support Response Monitoring in Solid Tumor Trial
03 Jan 2017  |   Industry